Dorothy Romanus, lead author of the study, states «this analysis supports the value of multiplexed testing for EGFR and
ALK gene rearrangements followed by molecularly - guided therapy in decisions surrounding coverage of related testing and targeted therapy.
About 4 percent of NSCLCs are driven by genetic aberrations called
ALK gene rearrangements, according to Farace.
• Testing revealed
an ALK gene rearrangement when a sample of a patient's uterine leiomyosarcoma was profiled.
Not exact matches
«Rare genetic cause of peritoneal mesothelioma points to targeted therapy: Genetic
rearrangement in the
ALK gene found in young women with mesothelioma may be targetable with FDA - approved drugs.»
Now, through an unexpected observation and a meticulous study of patients seen at Brigham and Women's Hospital, BWH investigators have added a fourth cause to the list: a genetic
rearrangement in the
ALK gene, observed in three patients with peritoneal mesothelioma.
After enriching for CTCs, the researchers analyzed the samples for
ALK rearrangements and for an increase in the number of copies of the
ALK gene.
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (
ALK)
gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.